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1 INTRODUCTION 
 
1.1 Malignant Mesothelioma 
 
Mesothelial cells form the serosal lining of the pleural, pericardial and peritoneal cavities. Among 
the most undifferentiated cells of our body mesothelial cells are able to differentiate 
morphologically into epithelial-like cells or fibroblast-like cells (Carbone et al, 2002). Malignant 
mesothelioma (MM) is a rare but very aggressive tumour which arises from the mesothelial cells; 
the pleural subtype is the most frequent (80%) (Boutin et al,1998). Malignant pleural mesothelioma 
(MPM) is strongly related to asbestos and/or asbestos-like fibers exposure, moreover MPM etiology 
is linked to Simian virus 40 infection, radiation and genetic susceptibility. MPM is characterized by 
a long latency (interval between first exposure to risk factors and the development of the pathology) 
that ranges from 10 to 45 years. The incidence of MPM in Italy is 2.94/100.000 for men and 
1.06/100.000 for women. In those areas in which there were asbestos production factories, like for 
example Casale Monferrato in Piedmont region, the incidence rises to 43.7/100.000 for men and 
27/100.000 for woman (Centro di Riferimento per l’Epidemiologia e la Prevenzione Oncologica in 
Piemonte). According to epidemiologic studies, it is estimated that MPM mortality rates will 
continue to increase by 5-10% per year in most industrialized countries for the next 2-3 decades, 
despite asbestos abatement efforts. In Italy the peak will be reach in 2015 (Peto J. et al, 1999) 
(Figure 1). 
 
 
Figure 1. Observed (to 1989) and predicted (1990–2029) annual numbers of pleural cancer deaths in men in Italy. 
 
Prognosis of MPM is poor, the overall survival in no treated patients ranges from 4 to 12 months. 
(Pass et al, 2001). According to the amount of epithelial and spindle cells we can distinguish three 
histological subtypes: epithelioid, sarcomatoid and biphasic (Figure 2); they are associated with a 
different prognosis. The epithelioid subtype is considered the less aggressive and most responsive to 
treatments, with the best prognosis (Boutin et al, 1998; Robinson et al,2005).  
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Figure 2 Example of histological subtypes of MPM: A) Epithelioid B) Biphasic C) Sarcomatoid. Original 
magnification 20X 
 
 
1.2 Etiology and Pathogenesis 
 
1.2.1 Asbestos and Mesothelioma 
Prior to the 1950s, malignant mesotheliomas (MM) were extremely rare. The first documented case 
of mesothelioma, according to current diagnostic criteria, was published in 1947 (King et al, 1947). 
Asbestos is a generic name for a family of naturally silicate minerals with different carcinogenic 
potential (Mossman et al, 1990). The various types of asbestos are divided into two major groups: 
serpentine represented by crysotile, the most common and economically important form of asbestos 
in the Western World; and the amphiboles, which include crocidolite, the most oncogenic type of 
asbestos, amosite, anthophyllite, and tremolite. The link between asbestos fibers and MPM 
development is well established (Boutin et al, 1996; Bocchetta et al, 2007), moreover Qi et al. 
recently showed how chrysotile can cause transformation in human mesothelial cells via HMGB1 
and TNF-α signaling (Qi et al, 2013). Amphibole are very thin fibers (diameter 3µm) which have 
the capacity to reach the pleura either through the lymphatic, or by direct penetration and to cause 
fibrosis, pleural plaques, and eventually mesothelioma. Moreover  they can damage the mitotic 
spindle of the cell leading to aneuploid and DNA damage. (Ault et al, 1995; Kamp et al, 1995). A 
key mechanism by which asbestos causes the transformation of mesothelial cells has recently been 
elucidated: working with primary human mesothelial (HM) cells, Yang et al discovered that 
asbestos induces necrotic cell death with resultant release of HMGB-1 in the extra cellular space. 
HMGB-1 release causes a chronic inflammatory response, macrophage accumulation and the 
secretion of TNF-α, which in turn activates NF-kB, leading to the survival of HM cells that have 
accumulated genetic damage because of asbestos exposure (Figure 3) (Yang et al, 2010). 
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Figure 3 Mechanism of asbestos-induced pathogenesis. 
 
 
Erionite is an asbestos-like mineral more carcinogenic than asbestos to induce mesothelioma (Hill 
et al, 1990); Wagner and colleagues showed that mice injected with erionite develop MM in almost 
all cases, instead mice injected with asbestos fibers has MM in a lower percentage of cases (48%) 
(Wagner et al, 1985). Carbone linked erionite with endemic cases of mesothelioma in some Turkish 
villages of Cappadocia (Emri et al, 2002) (erionite is natural component of the stones of this region) 
and in North and South Dakota, showing that it is a serious cause of environmental pollution 
(Carbone et al, 2011). Some studies have shown that asbestos exposure causes activation of MAPK, 
phosphatidylinositol-3-kinase (PI3K)-AKT and the downstream mTOR (the target for rapamacyin) 
in MM (Altomare et al, 2005; Wilson et al, 2008). 
 
1.2.2 SV40 and mesothelioma 
Simian Virus 40 is a normal guest of macaque species of monkeys, it is a double circle DNA virus 
with two coding regions: early and late according to which is first coded. Early region codes T 
antigen (large T antigen) and t antigen (small t antigen). The ability to induce tumor transformation 
in the host cells is linked to the large T antigen, indeed it binds and inactivates essential tumor 
suppressor genes, like p53 and pRb, stimulates Met, Notch-1 and telomerase activity. (Carbone et 
al, 1997; De Luca et al, 1997; Cacciotti et al, 2001; Bocchetta et al., 2003; Foddis et al, 2002). 
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Hamsters intracardially injected with SV40 develop MM in the 60% of cases (6-9 months), as well 
as intrapleurally injected mice show MM in the 100% of cases (4-6months) (Cicala et al, 1993). In 
the 60’-70’, millions of people worldwide were injected with the inactivated (Salk) and early live 
attenuated (Sabin) forms of polio vaccines that were contaminated with SV40, however its ability to 
cause tumour in human is not very clear since several conflicting data have been reported. 
 
1.2.3 Genetic predisposition 
Some individuals develop mesothelioma following exposure to small amounts of asbestos, whereas 
others exposed to heavy amounts do not. Carbone et al. have reported mesothelioma clustering in 
several Turkish families in which up to 50% of members developed mesothelioma (Roushdy-
Hammady et al, 2001; Carbone et al, 2007). This incidence far exceeds that observed in cohorts 
exposed to high levels of asbestos (4.6%), suggesting a genetic predisposition. Afterwards Carbone 
et al focused on two American families with high incidence of mesothelioma to identify putative 
mesothelioma susceptibility genes. The members of these families were neither exposed to erionite 
nor had occupational exposure to asbestos, thus removing the confounding factor of heavy exposure 
to carcinogens known to cause a high incidence of mesothelioma. Family members developed 
various malignancies, although mesothelioma predominated (Testa et al, 2011). Array-comparative 
genomic hybridization (CGH) analysis of two tumors (one per family) uncovered alterations 
encompassing or adjacent to the BAP1 (BRCA-1 associated protein 1) locus at 3p21.1. BAP1 
germline mutations have been also liked to uveal melanoma and to a type of benign melanocytic 
tumors that called mBAITS (melanocytic BAP1-mutated atypical intradermal tumours (Carbone et 
al, 2013) suggesting that BAP1 may rather represent gene predisposing to a new cancer syndrome. 
 
1.2.4 Radiation  
Radiation exposure has also been linked to MM, even though these cases are rarely observed 
(Goodman et al, 2009). Patients who received radiation treatments, specifically in the thoracic or 
abdominal regions, or who received Thorotrast intravascularly  have shown increased risks in 
developing MM (Amin et al, 2001). Moreover, studies in rats demonstrate that radiation is a 
causative co-factor of MM in combination with asbestos exposure (Lafuma et al, 1980). 
 
In summary, the association between asbestos, erionite, SV40 infection, genetic predisposition and 
radiation exposure suggests a multifactorial origin for malignant mesothelioma and each factor 
plays a crucial role in necrosis, inflammation and genetic damage.  
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1.3 Clinical features 
 
The mean age at presentation is 60 years, because of the long latency from the time of first exposure 
to asbestos to the development of clinically evident disease (Britton M., 2002). The incidence is 
higher in men, presumably because more men have worked in asbestos-related trades. Symptoms 
and physical findings are generally not specific for the disease. Most patients present with non-
pleuritic chest pain or dyspnea. Compared to that of metastatic pleural diseases, the pain from 
mesothelioma can be severe, aching, and often very difficult to control. Less common complaints 
are cough, fevers, chills, sweats, and fatigue. Fatigue, cachexia and pain are common in advanced 
disease. Physical examination is usually only remarkable for signs related to the presence of a 
pleural effusion or mass. Later in the course of disease one can often appreciate volume loss and 
decreased mobility of the chest wall on the side of the primary tumor. Occasionally, the tumor may 
extend directly into the chest wall, and be detected as a tender or non-tender chest wall mass. 
 
 
1.4 Diagnosis 
 
Diagnosis of malignant mesothelioma requires a careful evaluation of the clinical and radiological 
features, and it must be confirmed by a pleural biopsy.  
The main radiologic techniques used to diagnose mesothelioma are:  
 
• Computer Tomography (TAC) TAC is able to detect pleural effusion, pleural thickening, 
calcification, intralobular thickening and the potential thoracic invasion. However TAC 
cannot distinguish between benign tumour, adenocarcinoma and mesothelioma. TAC 
scanning may help fine needle aspiration/biopsy of pleural mass. 
• Magnetic resonance Imaging (MRI) MRI scanning allows to determine tumour size and to 
better detect the tumor area and distinguish the normal part. MRI is more accurate than TAC 
to evaluate the mediastinic lymphonodal enlargement.  
• Positron emission tomography (PET) PET imaging is a nuclear technique that produces 
three-dimensional image, it is currently the better way to locate the onset tumor sites. 
Fluorodeoxyglucose PET and particularly PET/CT shows promise as a tool to differentiate 
benign from malignant disease and as an adjunctive tool for staging. A combination of the 
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imaging techniques may be necessary for determining the best approach to the patient 
(Wang et al, 2004). 
 
Histology 
In order to obtain a definitive diagnosis of MPM the tissue biopsy and/or pleural effusion exams are 
essential. The pleural effusion often shows high level of bloody cells, high protein concentration, 
low level of white cells and low pH. The high content of hyaluronic acid is suggestive of 
mesothelioma, but it is poorly specific, so the cytologic analysis, as well as the trans-needle 
aspiration rarely leads to a definite diagnosis. The histological evaluation of pleural biopsy is 
therefore of crucial support to the diagnosis. However, in many cases, to confirm the MPM 
diagnosis it is necessary to investigate a panel of tumoral markers by the mean of 
immunohistochemistry. According to the embryologic histogenesis of mesothelial tissue, MPM 
shows epithelial and mesothelial markers such as cytocheratin 5/6, carletinin, thrombomodulin, 
mesothelin and the Wilms Tumor 1 (WT-1). The presence of at least two of positive markers in the 
context of a clinical and histological suspicion, is sufficient to confirm the diagnosis of MPM 
(Chierieac et al, 2009). Very often the diagnosis of MPM occurs in its late stage. TNM-based 
staging system by the International Mesothelioma Interest is the most widely used staging system 
for MPM (Rusch, 1995), it can be summarized as in Figure 4. 
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Figure 4 IMIG Staging System for Malignant Pleural Mesothelioma. 
 
 
1.5 Therapy 
 
There are no therapeutic standards for malignant mesothelioma and the treatment options depend on 
performance status, pulmonary function, stage, and age of the patient. 
 
 
1.5.1  Surgery  
The two potential goals of surgical therapy for pleural mesothelioma are palliation of symptoms and 
debulking of tumor with therapeutic intent. For surgical debulking of mesotheliomas, two surgical 
approaches are commonly employed, pleurectomy with decortication or extrapleural 
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pneumonectomy (EPP). Pleurectomy with decortication removes all gross disease from all pleural 
surfaces and preserves the underlying lung. EPP entails en bloc removal of the lung along with 
surrounding parietal pleura, pericardium, and diaphragm, with the pericardium and diaphragm then 
replaced by synthetic grafts. These are both technically challenging procedures and should be 
performed only by surgeons with extensive experience. EPP is especially difficult, and was 
originally associated with an unacceptably high morbidity of 30%. However, with advances in 
surgical, anesthetic, and critical care techniques, and more exacting patient selection, experienced 
centers now report mortality rates of < 4%, a rate comparable to standard pneumonectomy 
(Sugarbaker et al, 1999). 
 
1.5.2 Radiation therapy 
Although in vitro studies suggest that mesothelioma is more sensitive to radiation than non-small 
cell lung cancer (Charmichael et al, 1989), the clinical experience reported by radiation oncologists 
suggests that it is an especially radio-resistant tumour. In addition, radiation of the involved chest is 
limited by the presence of radiosensitive organs and the extensive nature of the tumour. As a 
consequence, its use appears limited to adjunctive therapy for patients who have undergone EPP, 
and to palliative treatment of painful chest wall lesions. Prophylactic chest wall irradiation may 
reduce the incidence of chest wall recurrences at incision sites but there is no consensus on its use 
and randomized controlled trials are needed (Lee et al, 2009). An area of active ongoing research is 
the role of high-dose hemithorax irradiation after EPP for early stage disease. In carefully staged 
patients, this approach has resulted in a marked reduction in local tumor recurrences, although 
nearly one half of patients subsequently developed isolated distant metastases (Senan et al, 2003). 
 
1.5.3 Chemotherapy 
Most patients with mesothelioma are not candidates for surgical or radiotherapy treatment and 
chemotherapy is their main option. The most commonly regimen used now includes the 
multitargeted antifolate drug pemetrexed with a platinum drug such as cisplatinum. The use of this 
combination has been compared to cisplatin alone in a large Phase III study of 456 patients 
(Vogelzang et al, 2003). Response rates were significantly better in the pemetrexed/cisplatin arm 
than in the cisplatin alone arm (41.3% Vs 16.7%), and survival was significantly better as well 
(median survival 12.1 months Vs 9.3 months). Addition of folic acid and vitamin B12 significantly 
reduced toxicity without altering survival benefit. The other regimen used commonly is the false 
nucleotide gemcitabine with a platinum agent. Nearly half of the patients on this doublet regimen 
noted symptom improvement, 33% had a partial response, and 60% had stable disease; no survival 
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benefit was demonstrated compared to historical controls (Novak et al, 2002). Similarly, treatment 
with the combination of gemcitabine and oxaliplatin has been reported to improve symptoms, but 
not significantly improve survival (median survival of 13 months) (Schutte et al, 2003). Platinum 
compounds act through the formation of platinum-DNA adducts. Removal of these adducts, which 
leads to chemoresistance, is mainly carried out by the nucleotide excision repair (NER) system that 
consists of at least 30 identified polypeptides, including the pivotal protein excision repair cross-
complementing group-1 (ERCC1) (Sancar A., 1995). It is hypothesized that low expression of 
ERCC1 might predict increased sensitivity to platinum-based chemotherapy, possibly due to the 
saturation of the enzyme complex; conversely, high levels of ERCC1 may predict a resistance to 
platinum-based chemotherapy. Pemetrexed (commercial name Alimta), is a multitargeted 
antifolate agent that inhibits dihydrofolate reductase (DHFR), thymidylate synthase (TS), and 
glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in purine and 
pyrimidine synthesis. However, pemetrexed is a weak inhibitor of GARFT, and when TS is 
inhibited, tetrahydrofolate oxidation stops and there is no longer a need for DHFR activity 
(Chattopadhyay et al, 2007). Therefore, most studies have focused on pemetrexed effects on TS. TS 
mRNA levels were inversely correlated with pemetrexed activity in different tumor cells (Hanauske 
et al, 2007; Giovannetti et al,2008), whereas other studies suggested a correlation between high 
levels of TS protein expression and reduced sensitivity to pemetrexed in colon and lung cancer cells 
(Sigmond et al, 2003). 
 
1.5.4 Immunotherapy 
It is known that an immune response is induced by mesothelioma, but it is weak (Robinson et al, 
2000). This knowledge has prompted a number of investigators to study different ways to 
consolidate that response. The intrapleural instillation of cytokines is limited by the short half-life 
of most cytokines, necessitating repeated injections or continuous infusion via a pleural catheter. 
Intrapleural interferon-gamma twice weekly for 2 months was reported to induce response rate of 
56% in early stage disease (Boutin et al, 1991). A continuous intrapleural infusion of interleukin-2 
induced a partial response in four of 21 patients and an overall survival of 16 months (Goey et al, 
1995). In both cases, side effects were minimal and consisted primarily of fever and constitutional 
symptoms. Studies in animals suggest that interferons have an antiproliferative effect on 
mesothelioma cells and enhance the cytotoxic effect of cisplatin. The results from these studies led 
to the development of a Phase II trial of cisplatin-doxorubicin and interferon alpha-2 in advanced 
malignant mesothelioma. The overall response rate was 29% and the median survival was 9.3 
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months with a one year survival of 45% and two year of 34% (Parra et al, 2001). However, severe 
myelosuppression was seen in 60% of patients limiting the application of this treatment. 
 
1.5.5 New agent under study 
Studies of the molecular biology of mesothelioma and the cellular mechanisms leading to a 
malignant phenotype have led to the identification of several possible therapeutic targets for 
treatment of this disease. Some of these are already under investigation in clinical trials, for 
example, several receptor tyrosine kinases are aberrantly expressed in these tumors, including the 
epidermal growth factor receptor (EGFR) (Janne et al, 2002). Other novel agents targeting growth 
factors found to be overexpressed in mesothelioma, e.g. vascular endothelial growth factor and its 
receptor, are under investigation. Other agents under study include anti-angiogenic agents, e.g. 
AZD2171, thalidomide and PTK/ZK787, inhibitors of histone deacetylase superoylanilide and 
hydroxamic acid (SAHA), proteasome inhibitors, and histone deacetylase inhibitors (PXD101). 
Furthermore, two classes of EGFR antagonists, small molecule tyrosine kinase inhibitors (TKIs) 
and monoclonal antibodies (mABs), have been approved by the Food and Drug administration 
(FDA) and the European Medicines Evaluation Agency (EMEA) for the treatment of metastatic 
NSCLC, colorectal cancer (mCRC), squamous-cell carcinoma of the head and neck and pancreatic 
cancer (Gridelli et al, 2007; Sridhar et al, 2003). Gefitinib and erlotinib, two reversible TKIs, inhibit 
the EGFR phosphorylation and its downstream cascade by blocking the ATP pocket located in the 
intracellular catalytic domain of the receptor. Cetuximab and panitumumab, two anti-EGFR mABs, 
target the extracellular domain of the receptor and upon the receptor binding they inhibit its 
dimerization and subsequent phosphorylation and signal transduction (Figure 5). The introduction 
of cetuximab and panitumumab in clinical practice, either in combination with chemotherapy or as 
single agent, has shown to improve the outcome of metastatic CRC and NSCLC patients (Saltz et 
al, 2004). Preclinical studies have shown that EGFR TKIs are highly efficacious in mesothelioma 
cell cultures (Barbieri et al, 2011), but two phase II studies of gefitinib and erlotinib used alone to 
treat malignant pleural and peritoneal mesotheliomas failed to demonstrate their clinical efficacy. 
However it needs to be pointed out that the patients in both trials were not selected on the basis of 
any molecular criteria (Govindan et al, 2005; Garland et al, 2007). One recent study has shown that 
cetuximab effectively blocks the growth of MPM cells in cell cultures and mouse models (Kurai et 
al, 2012) and, as in the case of colorectal cancer and lung adenocarcinomas, the potential efficacy 
of these TKIs in MPM may depend on the mutation status of EGFR gene and its downstream 
effectors (Lie`vre et al, 2006). To the best of our knowledge, only a few low-powered studies have 
investigated the presence and frequency of EGFR gene mutations in MPM (Cortese et al, 2006; 
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Enomoto et al, 2012), and none has searched for mutations in the KRAS, BRAF, and PI3KCA 
downstream effectors.  
 
 
Figure 5 EGFR inhibitors, mABs and TKIs. 
 
 
1.6 Epidermal growth factor receptor (EGFR). 
 
Epidermal growth factor (EGF) was first discovered by Stanley Cohen in 1960 during his study of 
nerve growth factor in mouse sub-maxillary glands and subsequently, in 1975, he confirmed the 
presence of plasma membrane receptors in human fibroblasts (Cohen et al, 1960, Carpenter et al, 
1975). EGFR was isolated in 1982 as a 170 kDa transmembrane glycoprotein with an EGF binding 
site on the extracellular surface (Cohen et al, 1982). The structure of EGFR was found to be the 
human equivalent of the mammalian v-erb-B oncogene protein from the avian erythroblastosis 
virus. Unlike the human EGFR, the v-erb-B oncogene protein did not have the extracellular EGF 
binding domain thereby demonstrating that the intracellular domain may play an important role in 
tumourigenesis. EGFR belongs to the human epidermal growth factor receptor (HER) family, which 
has four structurally related receptor tyrosine kinases. The EGFR gene localized on chromosome 7 
p11-13, the protein consists of 1186 amino acids. The receptor structure consists of extracellular, 
transmembrane and intracellular domains. The extracellular domain consists of cysteine-rich 
clusters, which form the ligand-binding domain. Upon binding with ligands such as EGF or 
transforming growth factor alpha (TGF-α), the EGFR monomers form homodimers with another 
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EGFR or heterodimers with another receptor of the HER family. The intracellular domain has 
tyrosine kinase activity. Dimerisation of the EGFR results in structural rearrangement of the 
intracellular tyrosine kinase domain, adenosine triphosphate (ATP) is then recruited into the 
catalytic domain, resulting in its auto-phosphorylation. This leads to the activation of a cascade of 
intracellular signal transduction pathways resulting in cell proliferation, anti-apoptosis, invasion and 
metastasis (Citri et al, 2006; Hynes et al, 2005; Bogdan et al, 2011). Among a host of various 
intracellular signalling pathways stimulated by EGFR, the major pathways activated are the 
RAS/RAF/MAPK pathway resulting in cell proliferation, metastasis and invasion, and the 
PI3K/AKT/mTOR pathway resulting in inhibition of apoptosis (Ciardello et al, 2008) (Figure 6). 
The first signaling cascade shown to be downstream of the EGFR was the Ras–mitogen-activated 
protein kinase or MAP kinase pathway. When the pathway is activated, the SOS guanine nucleotide 
exchange factor is recruited to the plasma membrane via the Grb2/Drk/Sem5 adapter protein. SOS 
stimulates the exchange of GTP for GDP on the small G-protein Ras. Subsequently activated Ras 
stimulates the MAP kinase pathway to promote cell proliferation. Phosphoinositide 3-kinase (PI3K) 
plays a crucial role in effecting alterations in a broad range of cellular functions in response to 
extracellular signals. A key downstream effector of PI3K is the serine-threonine kinase Akt which 
in response to PI3K activation, phosphorylates and regulates the activity of a number of targets 
including kinases, transcription factors and other regulatory molecules (Paez et al, 2000). The 
complexity of signaling is further increased by cross-talk between individual pathways. Since 
EGFR is associated with an oncogenic phenotype, its inhibition may result in an anti-neoplastic 
effect. As mentioned before, in the last decade several inhibitors of EGFR have been developed, 
including monoclonal antibodies (cetuximab) and small molecule inhibitors (gefitinib, erlotinib), 
which have been shown to be effective in animal models, in preclinical and clinical studies 
(Mendelsohn et al, 2003). A correlation between EGFR expression and response to therapy has 
been reported in some human cancers (breast, lung and prostate) (Santoro et al, 2004; Cappuzzo et 
al, 2003). 
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Figure 6 EGFR downstream signaling pathways 
 
 
 
 
1.6.1 EGFR mutations and inhibitors 
Activating EGFR mutations have been reported in cancers such as non-small-cell lung cancer 
(NSCLC) and head and neck cancers, and are predictive of the response to gefitinib or erlotinib 
therapy (Lynch et al, 2004; Paez et al, 2004; Lee et al, 2005). Approximately 90% of EGFR 
mutations affect small regions of the gene within exons (18 to 24) that code for the EGFR tyrosine 
kinase domain. The most common mutations are an in-frame deletion in exon 19 around codons 746 
to 750 (accounting for 45 to 50% of EGFR mutations) and a missense mutation leading to a 
substitution of arginine for leucine at codon 858 (L858R) in exon 21 (35 to 45% of EGFR 
mutations) (Sharma et al, 2007). Somatic EGFR mutations are found in approximately 5 to 15% of 
unselected white patients and in 25 to 35% of unselected Asian patients with NSCLC. These 
mutations seem to be limited to NSCLC, since they have rarely been detected in other types of 
human cancer. 
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1.7 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
 
KRAS is a small GTPases that regulate cell growth, proliferation and differentiation, it is normally 
activated in response to the binding of extracellular signals, such as growth factors, RTKs (Receptor 
Tyrosine Kinases) and TCR (T-Cell Receptors). In the resting cell, KRAS is tightly bound to GDP 
(Guanosine Diphosphate); as a result of extracellular stimuli to cell membrane receptors the guanine 
nucleotide exchange factors (GEFs) release GDP and allow GTP (Guanosine Triphosphate) 
binding. In the GTP-bound form, KRAS interacts specifically with effector proteins, thereby 
initiating cascades of protein-protein interactions that may finally lead to cell proliferation. Active 
GTP-bound KRAS interacts with several effector proteins: among the best characterized are the Raf 
kinases and phosphatidylinositol 3-kinase (PI3K) (Hancock JF., 2003). KRAS gene is localized on 
chromosome 12. More than 95% of KRAS activating gene mutations occurs at codon 12 and 13 of 
exon 2. Less frequent mutations occurs at codon 61. KRAS activating mutations cause resistance to 
anti-EGFR mABs target therapies.  
 
1.8 v-raf murine sarcoma viral oncogene homolog B1 (BRAF) 
 
BRAF gene is localized on chromosome 7q34, it encodes the protein BRAF belonging to the raf/mil 
family of serine/threonine protein kinases. This protein plays a role in regulating the MAP 
kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion, in fact 
activated BRAF triggers mitogen-activated protein kinase (MAPK) and extracellular-signal 
regulated kinase (ERK, MEK1 and MEK2) by serine phosphorylation. Mutations in BRAF gene are 
associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental 
retardation and a distinctive facial appearance. Mutations in this gene have also been associated 
with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, 
thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. The highest 
frequency of BRAF mutations is in malignant melanoma. The most common mutation is a T to A 
nucleotide transversion leading to a V600E amino acid substitution within the activation segment of 
the Raf serine/threonine kinase gene product, increases the catalytic activity of B-Raf and leads to 
subsequent activation of MEK and ERK MAPKs (Davies et al, 2002: Pollock et al, 2003). Since 
constitutively active BRAF mutants commonly cause cancer by excessively signaling to cell 
growth, inhibitors of BRAF have been developed for both the inactive and active conformations of 
the kinase domain as cancer therapeutic candidates (Bollag et al, 2010; Wan et al, 2004). Sorafenib 
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and Vemurafenib are currently the two BRAF molecular inhibitors approved by the FDA for the 
treatment of primary liver and kidney cancer and for late stage melanoma. 
 
1.9 Phosphoinositide 3- kinase (PI3K) 
 
The class I PI3Ks catalyse the conversion of phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P2) 
to phosphatidylinositol-3,4,5- trisphosphate (PtdIns-3,4,5-P3). These specialized lipids serve to 
recruit pleckstrin homology (PH) domain-containing proteins such as the serine-threonine kinase 
Akt and PDK1 (phosphoinositide-dependent kinase 1) to the plasma membrane. After recruitment 
to the membrane, Akt is phosphorylated and consequently activated, by PDK. In turn, Akt 
phosphorylates multiple proteins on serine and threonine residues. Through phosphorylation of 
these targets, Akt carries out its role as a key regulator of a variety of critical cell functions 
including glucose metabolism, cell proliferation and survival. The PI3K family comprises eight 
members divided into three classes according to their sequence homology and substrate preference. 
PI3K enzymatic structure shows a catalytic subunit (p110) associated with a regulatory one (p85). 
The catalytic subunit PI3KCA is encoded by a gene localized at chromosome 3p26.32. Mutations in 
the PIK3CA gene are not frequent in colon rectal cancer, occurring in about 15% of these tumours. 
PIK3CA mutations mainly occur in exons 9 and 20, with exon 9 showing the highest incidence 
(68.5% approximately). These mutations can be found in the same tumour together with KRAS and 
BRAF mutations, and this makes difficult to evaluate their own role in defining the sensitivity to 
anti-EGFR mAbs. (Benvenuti et al, 2008; Samuel et al, 2004; Di Nicolantonio et al, 2010). 
 
1.10  Prognostic and predictive biomarkers. 
 
In the majority of patients MPM is diagnosed in stage III/IV, and systemic therapy represents the 
only potential treatment option for most cases. The combination of platinum or cisplatin and 
pemetrexed represents the standard of care in the first-line treatment of MPM. Several studies 
carried out on NSCLC showed that protein and mRNA ERCC1 expression have a consistent 
prognostic and predictive value in patient treated with cipslatin (Olaussen et al, 2006; Zheng et al, 
2007). Similarly, in NSCLC cell lines, high baseline TS gene expression levels confer resistance to 
pemetrexed and TS protein levels are correlated to pemetrexed efficacy in a variety of solid tumours 
(Gomez et al, 2006; Rose et al, 2002; Zucali et al, 2011; Righi et al, 2010). Due to the epithelioid 
phenotype of the most part of MPM it could be interesting to investigate the ERCC1 and TS 
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gene/protein expression in order to determine whether they can have a prognostic and/or predictive 
value in mesothelioma patients. 
 
1.10.1 Excision repair cross-complementing group-1 (ERCC1) 
Platinum compounds function by binding to DNA resulting in intrastrand or interstrand crosslinks, 
which disrupt the DNA structure. These lesions may interfere with base pairing and generally 
obstruct transcription and normal replication processes, ultimately leading to apoptosis. The 
nucleotide excision repair (NER) pathway is 1 of 5 recognized DNA repair pathways (mismatch 
repair, double-strand break repair, base excision repair and direct repair) that maintain DNA 
integrity and defend DNA against environmental damage. It is generally well accepted that each of 
the repair pathways identifies distinct lesion types (Hoeijmakers, 2001). NER has been identified to 
repair bulky, helix-distorting DNA lesions caused by UV light or chemicals, including platinum 
compounds. NER pathway acts through the recognition of DNA repair, followed by the formation 
of a complex to unwind the damage portion and excise it. Finally, the excised area is resynthesized 
and bound to the undamaged DNA, restoring the double helix. After the repair process is complete, 
the entire complex is disassembled. Excision repair cross-complementation group 1(ERCC1) 
protein functions within the repair complex as it heterodimers with the Xeroderma pigmentosum 
complementation group F (XPF) protein and functions as an endonuclease producing a 5’ single 
strand cut of 20 nucleotides from the lesion (Figure 7). Early reports suggested that ERCC1 mRNA 
levels, and not XPF, were correlated with DNA repair capacity when exposed to UV light, 
suggesting that ERCC1 might be rate-limiting (Bohanes et al, 2011; Vogel et al, 2000). Those data 
suggest the hypothesis that ERCC1 gene expression might be used as a predictive marker for DNA 
repair capacity, and thus predict platinum compounds cytotoxicity. ERCC1 gene localized on 
chromosome 19q13.32 and encodes a 32 kDa protein located in the nucleus. 
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Figure 7 Simplified model of genome Nucleotide Excision Repair (NER) system. 
 
 
1.10.2 Thymidylate synthase (TS) 
Thymidylate synthase (TS) is a key enzyme in the de novo synthesis of DNA. The reaction 
catalyzed by TS is the methylation of dUMP, through the transfer of the methyl group provided by 
the cofactor methylenetetrahydrofolate (CH2THF) dUMP is converted into deoxythymidine-5′-
monophosphate (dTMP). Subsequently, dTMP is phosphorylate by two successive steps to 2’-
deoxythymidine-5’-triphosphate (dTTP) an essential precursor for DNA synthesis. TS is target for 
chemotherapeutic agents because of its central role in DNA synthesis, and it is also of interest 
because of its rich mechanistic features. Pemetrexed and 5-fluorouracil are the main antitumour 
agents targeted to the TS (Figure 8). The gene encoding TS is localized on chromosome 18p11.32, 
the protein consists of 313 amino acids and has a ubiquitous localisation in the cell, i.e. in the 
nucleus, in the cytoplasm and in the mitochondrion inner membrane and matrix. 
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Figure 8 a) Simplified illustration of some key enzymatic reactions of folate metabolism, showing enzymes affected 
by pemetrexed, or its polyglutamates. b) Structure of pemetrexed disodium. AICARFT: aminoimidazole carboxamide 
ribonucleotide formyltransferase; DHFR: dihydrofolate reductase; GARFT: glycinamide ribonucleotide 
formyltransferase; THF: tetrahydrofolate, TS: thymidylate synthase. 
 
 
1.11  Clonality analysis 
 
In spite of a number of different approaches that have been shortly described above, malignant 
mesothelioma is not yet to be cured. Understanding more about the initiation of the tumor 
development and the factors that trigger it is crucial to have the best way to treat or even prevent 
this cancer. Given the fact that a cell population could be a mixture of slightly different cells, any 
single method for the treatment may include the chance of the failure, because of the differences of 
drug sensitivity of the single cells. The most common method to investigate whether a tumour 
population is homogenous or not is to determine its clonal origin. This approach explores the nature 
of tumour initiation and categorizes the tumour as mono- or poly-clonal. A clonal population of 
tumour cells is defined as those cells arising from the mitotic division of a single somatic cell 
(Seeker-Walker et al, 1985), while a polyclonal tumor is known to be initiated by division of 
multiple differentiated cells. Categorization of a cell population as mono- or polyclonal is made 
possible by the determination of the inactivated X chromosome of the cells in a given population. 
The natural event of X chromosome inactivation occurs in all female cells during the early 
embryogenesis and provides a sufficient tool for tracking a population to their ancestral stage, 
because once it is determined, the same X chromosome is kept inactivated during the mitosis of the 
same cell.  
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1.11.1 X Chromosome inactivation 
In females inactivation of one X chromosome occurs in each somatic cell in early embryonic 
development and is passed onto the progeny of the cell in a stable fashion (Lyonization) (Martin et 
al, 1978; Lyon et al, 1988, Lyon, 1961). Females heterozygous for polymorphic X-chromosome 
genes are therefore mosaics with respect to X-chromosome activity (Figure 9). In 1961, Mary Lyon 
proposed that the Barr body, a unique cytological entity situated near the nucleolus that 
distinguishes female from male cells, was the condensed, inactive female X chromosome. She 
proposed random X‐chromosome inactivation (XCI) as an explanation for this cytological entity. 
The Lyon hypothesis suggested that one of the two X chromosomes is entirely silenced or 
inactivated at random in the soma to balance the X‐linked gene dosage between XX females and 
XY males. Her hypothesis was based on the observations of X-linked coat color mutations in 
heterozygous female mice. In these mice, the phenotype was always a mosaic, consisting of patches 
of normal or mutant color, rather than a homogenous blending, suggesting that early in 
development, in the pigmented cells either one or the other X chromosome was inactivated. Thus, if 
the X chromosome carrying the mutant allele was inactivated, the patch was of normal color, 
whereas if the X chromosome carrying the normal allele was inactivated, the patch was of mutant 
color. Beutler and colleagues formulated the XCI hypothesis using studies of the human X 
chromosome glucose 6-phosphate dehydrogenase (G6PD) gene (Beutler et al, 1962). They found 
that, in females, G6PD activity was not twice as much that of males, as expected by the presence of 
two X chromosomes, and postulated a dosage compensation mechanism. In females heterozygous 
for G6PD deficiency, dosage compensation results in G6PD expression at half the rate of normal 
hemizygous males. This could be attributable to either half-level activity in all cells or normal 
expression in some cells and low expression in other cells, resulting in overall half-level expression. 
Using a mixture of male cells with deficient G6PD activity and normal G6PD activity, Beutler and 
colleagues measured G6PD activity (by glutathione stability) and compared it with the response of 
female erythrocytes. They found that the response curves of the 2 samples were similar in shape and 
concluded that intermediate activity in females was probably attributable to the same mechanism as 
in the mixture of male normal and G6PD activity-deficient erythrocytes. There is evidence that X-
chromosome inactivation is related to differential methylation of cytosine in the DNA of X-
chromosome genes (Holliday R, 1987). 
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Figure 9 X chromosome inactivation Xp: clonal cell with active paternal X chromosome Xm: clonal cell with active 
maternal X chromosome 
 
 
1.11.2 Mechanisms of X-chromosome inactivation 
The exact molecular mechanisms underlying XCI are still not fully clarified, but involve several 
steps, including the determination of the number of X chromosomes per cell, selection of either the 
paternal or maternal X chromosome for subsequent inactivation, and initiation of the actual 
inactivating process. It has been demonstrated in mice that there are 3 non coding loci, located near 
the center of inactivation of X chromosome that play a pivotal role in the mechanism of X-
chromosome inactivation. These loci are: non coding RNA X (inactive)-specific transcript (Xist), its 
antisense partner Tsix, and the intergenic locus Xite. Xist is necessary for cis inactivation of the X 
chromosome. In vitro, Xist is able to silence also the autosomal surrounding chromatin in case of X: 
autosome translocation, but in an incomplete manner, due to instability of autosome inactivation 
(Lee J.T et al, 1999). Tsix and Xite work in parallel to Xist by maintaining X-chromosome 
transcriptional competence (Ogawa et al, 2003). Although the functions of these 3 loci have been 
deduced using complementary cell lines, the actual physical interactions of these components are 
less well known. Xist is proposed to achieve cis-inactivation of the X chromosome through close 
interactions between its RNA transcript and the segment of X chromosome to be inactivated (Penny 
G.D. et al, 1996). The putative trans-interactions, based on the need to determine one X to be 
exclusively activated and the other X to be exclusively inactivated, remained elusive, until the 
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recent demonstration that the 2 X chromosomes undergo inter-chromosomal pairing (Heard E., 
2004). It is remarkable that inter-chromosomal pairings typically occur in germ cells undergoing 
meiosis, rather than in somatic cells undergoing mitosis. X-chromosome inactivation timing is 
crucial to the interpretation of X chromosome inactivation pattern (XCIP)-based clonality assays. It 
has been assumed that pre-blastocyst embryos express both X chromosomes and that inactivation 
did not occur until after implantation and the embryonic stem cells began to differentiate into 
separate cell lineages (Okamoto et al, 2004). Recent experiments, however, demonstrate that XCI 
occurs as early as the 4-cell stage of the embryo, but is variable and leaky and does not become 
stabilized until after implantation, but before differentiation of embryonic stem cells into the various 
cell lineages (Huynh et al, 2003). XCI before cell lineage differentiation is crucial for the 
interpretation of XCIP clonality studies. Hematopoietic cell lines derive not from a single 
embryonic stem cell but from several progenitors, allowing for the mosaic expression of genes from 
both X chromosomes (Prchal et al, 1996). 
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2 AIMS OF THE STUDY 
 
1) Given that only a few low-powered studies have investigated the presence and frequency of 
EGFR gene mutations in malignant pleural mesothelioma (Cortese et al, 2006; Enomoto et 
al, 2012), and none has searched for mutations in the KRAS, BRAF and PI3KCA 
downstream effectors, in this study we searched a large series of histological MPM samples 
for mutations in EGFR gene and its main downstream signaling effectors in order to 
evaluate their frequency and possible prognostic significance, and their possible use as 
predictors of the response of MPM to targeted therapies. 
 
2) The golden standard in the treatment of patients with malignant pleural mesothelioma is the 
multimodal administration of platinum compounds and pemetrexed. Currently there are no 
biomarkers predicting the clinical outcome and the prognosis for this tumour. The second 
aim of this work was to retrospectively investigate in a series of MPM patients, randomly 
treated with platinum and pemetrexed (alone and in combination), ERCC1 and TS gene and 
protein expression to determine whether they can provide information about the clinical 
outcome and/or can have a prognostic value. 
 
3) Identifying whether a tumour is monoclonal or polyclonal at start have critical implications 
in terms of early therapeutic intervention. The third aim of the study was to evaluate the 
clonality pattern of malignant mesothelioma.  
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3 MATERIALS AND METHODS 
 
In this study we used two different clusters of MPM tumour samples: in the first case we collected 
the samples from the Thoracic Unit of the University Hospital of Novara on which we performed 
the sequencing analysis of EGFR and downstream pathways and the evaluation of ERCC1 and TS 
protein and gene expression (Novara samples).  
In the second case the tumour samples we used to evaluate the clonality assessment of malignant 
mesothelioma were obtained from Dr. H. I. Pass (NYU, New York) and from Dr.Paul Sugarbaker 
(WCI, Washington, DC) in accordance with protocols approved by the Institutional Review Board 
of each center and upon patients informed consent (US samples). 
 
3.1 Novara samples 
 
3.1.1 Samples collection and preparation 
In this study we involved a large number of MPM patients admitted to the Thoracic Unit of the 
University Hospital of Novara between January 2008 and March 2013, all of whom were diagnosed 
as MPM on the basis of multiple pleural biopsies taken by means of video-assisted thoracoscopy. 
The tumour samples were immediately fixed in formalin for 24 h, embedded in paraffin, and 
routinely processed for histology and immunohistochemistry. The diagnosis of MPM was based on 
standard histological and immunohistochemical criteria, including positivity to calretinin, vimentin, 
and cytokeratins 5 and 6, and negativity to carcinoembryonic antigen, thyroid transcription factor 1, 
and Ber Epy 4. From the analysis of the clinical records we obtained the following data: 
 
• Personal data of the patient 
• MPM diagnosis date 
• Surgery or biopsy date 
• Treatment  
• Status (Dead/Alive) 
• Follow up: from the date of diagnosis to June 2013 for patients alive, and from the date of 
diagnosis to the date of death for dead patients. 
 
The MPMs were classified on the basis of the WHO classification of pleural tumours (Travis et al, 
2004), and clinically and pathologically staged on the basis of the TNM staging system (Sobin et al, 
24 
 
2009). Looking through the WINANA database of the Pathology Department of “Maggiore della 
Carità” Hospital we got these data (snomed # M-90523):  
 
• haematoxylin/eosin-stained slides of the pleural biopsies and corresponding formalin-
fixed, paraffin-embedded blocks 
• histotype: epithelioid, sarcomatoid and biphasic.  
 
An expert pathologist reviewed the haematoxylin/eosin-stained slides of each case to: 
 
• confirm the diagnosis and the histotype; 
• select the area with 70% of tumour cells (minimum required for the sequencing analysis 
and gene expression evaluation); 
• identify the best sample, in term of cellularity, in case we have more than one biopsy or 
surgical specimen. 
 
The tumoral areas of the formalin-fixed paraffin-embedded sections were macro-dissected manually, 
and then five 5 µm thick sections were prepared and collected in a 1.5 mL tube in order to perform 
the DNA and RNA extraction. 3 µm thick sections were cutted to perform immunohistochemistry 
staining. 
 
3.1.2 DNA extraction 
Genomic DNA was extracted using 450 µl of EDTA-SDS/proteinase K (SDS 1%, EDTA 20mM, 
Tris HCl pH 7,5 20mM) followed by phenol-chloroform, and resuspended with 30 µL of DEPC-
treated and RNAse free water (Promega, Madison, USA). We include a negative control of 
extraction every 5 samples. The DNA concentration was evaluated by reading the absorbance at 
260nm by mean of a spectrophotometer (Eppendorf, Amburgo, Germania). The purity of DNA 
preparation were measured by evaluating 260/280 and 260/230 ratios. 
 
 
3.1.3 Mutational analysis 
 
EGFR gene 
All of the samples were analysed using the TheraScreen EGFR29 Mutation Kit (QIAGEN, 
Manchester, UK), which combines the two technologies of ARMS and Scorpion chemistry in order 
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to detect mutations in a real-time polymerase chain reaction (PCR). This kit allows the detection of 
in-frame deletions on exon 19, insertions on exon 20, and G719X, S768I, T790M, L858R and 
L861Q mutations against a background of wild-type genomic DNA with a sensitivity of 1%. PCR 
plate and reaction mix were performed according to the manufacturer’s instructions, with 50 ng of 
DNA for each well. DNA amplification was performed with the following cycles: denaturation at 
95°C for 4 min, 40 cycles of 95°C for 30 sec and 60°C for 1 min. Negative and positive controls 
were used in every reaction plate, moreover the kit contains a control reaction mix that amplify 
exon 2 of EGFR to evaluate amplifiable DNA in the tested samples. Results interpretation was done 
following the datasheet instruction: sample quantification cycle must be within the range of 21.92 
and 37.00. Sample was classified as positive when both control and mutation curves were positive 
according to the above limits. In order to determine the presence of other less common mutations, 
the samples underwent further PCRs in order to amplify the whole sequence of exons 18-21 of the 
EGFR gene. PCR conditions primers and are shown in Table 1. 
 
KRAS gene 
KRAS gene was analysed by means of a mutant-enriched PCR (ME-PCR) in order to detect the 
hotspots in codons 12 and 13 of exon 2 that include more than 95% of the known gene mutations. 
The ME-PCR consisted of two amplification steps (semi-nested PCR) in which artificial restriction 
sites were introduced into the wild-type amplicon using mismatched primers. The restriction sites 
(BstNI for codon 12 and BglI for codon 13) introduced during the first PCR step were localised 
immediately next to the KRAS codon in the analysis in order to distinguish wild-type and mutant 
sequences. The wild-type amplicons were then digested by restriction enzymes and the mutant 
products were enriched for a second round of amplification. Each round of amplification was 
followed by overnight digestion with BstNI and BglI restriction enzymes(10 U/ml); respectively for 
codon 12 we digested with BstNI at 60°C and for codon 13 with BglI at 37°C in a 20 µl reaction 
volume. Products of PCR amplification were analyzed by gel electrophoresis on 3% agarose gel 
containing Ethidium Bromide (10ug/ml), and resolved DNA bands were visualized on a UV 
transilluminator (MarcoVe UV-20, Hoefer). ME-PCR has a sensitivity of up to 0.01%. All of the 
samples were underwent automated sequencing by using an ABI PRISM 3130 (Applied 
Biosystems, Foster City; CA, USA) and reverse primers.  
 
BRAF gene 
Exon 15 of the BRAF gene (which contains the hotspot codon 600, where more than 90% of gene 
mutations occur) was analysed by means of direct sequencing after PCR reaction starting from 50 
ng of genomic DNA. The primers and PCR conditions are shown in Table 1. 
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PI3KCA gene 
The analysis of the PIK3CA gene was concentrated on exons 9 and 20, which include all of the 
hotspot codons, the primers and PCR conditions are shown in Table 1. The mutational status of 
PIK3CA was then investigated by means of direct sequencing. 
 
Sequence analysis  
All of the PCR products and KRAS second enzymatic digestions were analysed by means of 3% 
agarose gel electrophoresis, and then purified using NucleoSpin Gel and the PCR clean-up kit 
(Macherey-Nagel, Düren, Germany). The sequence of each gene was analysed using an ABIPrism 
3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), and all of the mutated cases 
were confirmed twice starting from independent PCR reactions.  
 
 
 
Table 1 Forward and reverse primers, PCR conditions and amplicon length of KRAS, EGFR, BRAF and PI3KCA 
exons investigated. 
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3.1.4 Protein and gene expression analysis. 
 
mRNA extraction and reverse transcription. 
RNAs were isolated from paraffin-embedded MPM tumor samples verified by an expert pathologist 
to contain at least 50% of tumor cells. After deparaffinization with xylene, RNA was isolated by the 
RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Applied Biosystems) following the datasheet 
instruction and resuspended in 60 µl of elution solution. RNA yields were checked by reading the 
absorbance at 260nm by mean of a spectrophotometer (Eppendorf, Amburgo, Germania). 500 ng 
sample of total mRNA was reverse transcribed to cDNA using RevertAid First Strand cDNA 
synthesis kit (Fermentas, St. Leon-Rot, Germany) using 0,2 µg/µL of random examers. 
 
Quantitative Real-time PCR. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed in triplicate with 3µl 
of cDNA, 1X of TaqMAn Universal PCR Master Mix no AmpErase UNG, 1X of premade TaqMan 
Gene Expression Assay (Assay ID: ERCC1: Hs01012161_m1; TS:Hs00426586_m1, Applied 
Biosystems) in a final reaction volume of 20 µl. Samples were amplified by the ABI 7500 real-time 
PCR machine (Applied Biosystems) under the following thermal profile: an initial incubation at 
95°C for 20 seconds, 40 cycles of denaturation at 95°C for 15 seconds followed by annealing and 
extension at 60°C for 30 seconds. Assay results were normalized to 18S rRNA (Eukaryotic 18S 
rRNA Endogenous Control; Applied Biosystems) and gene expression quantification was 
performed by ∆∆CT methods using Sequenze Detector System 7500 software v 2.0.4. We used as a 
calibrator a pool of normal tissues including lung, liver, colon and pleura. 
 
Immunohistochemistry 
Immunohistochemistry was performed on 3-µm thick tissue sections by using anti-ERCC1 (clone 
8F1, dilution 1:100; ThermoScientific, Erembodegem, Belgium) and anti-TS (clone TS106, dilution 
1:50; Dako, Glostrup, Denmark) monoclonal antibodies. ERCC1 immuno reaction was performed 
on Ventana BENCHMARK® XT instrument using UltraView DAB kit (Ventana Medical Systems, 
Tucson, USA), whereas DAKO Autostainer (Dako, Glostrup, Denmark) was used for TS 
immunostaining. For epitope retrieval, slides were exposed on heat EDTA, then, endogenous 
peroxidase activity was blocked by incubation with H2O2 3% (ERCC1: 30 min EDTA and 4 min 
H2O2– TS: 14 min EDTA and 10 min H2O2). ERCC1 primary antibody incubation was carried out 
for 32 minutes at 37°C while anti-TS incubation was performed for 60 minutes at room 
temperature. The reaction was revealed with EnVision HRP Rabbit/mouse detection system 
(DakoCytomation, Denmark), using 3’ 3-diaminobenzidine (Dako) as chromogen. Negative 
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controls were obtained omitting the primary antibody. Proliferating germinal center lymphocytes of 
a reactive lymph node and normal mesothelial cells adiacent the tumor served as positive controls 
for TS and ERCC1, respectively. (Olaussen KA et al. 2006; Zucali AP et al., 2011). The slides were 
counterstained with hematoxylin, dehydrated, and mounted.  
 
Immunohistochemistry evaluation. 
The sections were reviewed and scored by a pathologist that was blinded to patient identity and 
clinical outcome. In agreement with previous studies (Olaussen et al, 2006), the results were 
interpreted by a system on the basis of staining intensity and the number of stained cells. Staining 
for ERCC1 was considered positive when tumor cells showed nuclear reactivity, while TS 
positivity was on the basis of both nuclear and cytoplasmic reactivity. The percentage of positive 
tumor cells and the staining intensity were analyzed by a semiquantitative histological score (H-
score). In particular, the staining intensity of tumor—ranging from low (score 1) to moderate and 
high scores (2 and 3)—was multiplied by the percentage of positive neoplastic cells, in detail: 0 if 
0%, 0,1 if 1% to 9%, 0,5 if 10% to 49%, and 1 if 50% or more, thus obtaining values from 0 to 3.  
3.1.5 Statistical analysis. 
 
Mutational data analysis. 
The associations between categorical variables were determined using the chi-squared or Fisher’s 
exact test. The statistical differences of the average values were tested using a Student’s t test and 
analysis of variance followed by Bonferroni’s test. The impact of the different variables on long-
term outcomes was analysed using the Kaplan-Meier method of analysing disease specific survival 
(DSS); the survival data were compared using the log-rank test. P values of <0.05, with a 95% 
confidence interval, were considered statistically significant 
 
Biomarkers data analysis. 
Patient characteristics were described in terms of number and percentage, median and range. DSS 
was calculated from the time of diagnosis to the time of death (caused by the specific disease). DSS 
was evaluated with the Kaplan–Meier method and groups were compared with the Log-rank. The 
association between mRNA or H-score and the clinical-pathological features of the patients was 
analised respectively by the mean of Kruskal Wallis test and Fisher’s Exact test. The correlation 
between TS and ERCC1 gene expression was analised by the Pearson’s test, whereas the correlative 
analysis between TS and ERCC1 protein expression was carried out by the Kendall test. All the 
statistical analyses were performed using the R software. The level of significance was set at P=.05. 
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3.2 US samples 
 
US tumour samples derived from MM female patients who underwent surgery; they were collected 
at the following institutions: Department of Cardiothoracic Surgery, New York University, New 
York, NY; MedStar Washington Hospital Center, Washington, DC; University of Wisconsin School 
of Medicine and Public Health Department of Surgery, Madison, WI, and at the Department of 
Surgery, Penn Presbyterian Medical Center, Philadelphia, PA, in accordance with protocols 
approved by the Institutional Review Board of each center and upon patients informed consent. 
Human specimens tissues were collected during surgical tumour resection, immediately frozen and 
processed for laser microdissection and DNA extraction. The identification of tumour and normal 
tissues in each sample was performed by hematoxylin-eosin (H&E) staining.  
3.2.1 HUMARA Assay 
Tumors and normal tissues were dissected by Laser Capture Microdissection using a MMI CellCut 
Plus (Molecular Machines & Industries, MI, USA). LCM tubes were incubated for 48 hours at 37°C, 
centrifuged, and subjected to protein digestion for two additional days at 55°C, by adding fresh 
Proteinase K daily. DNA was extracted by using DNeasy Blood&Tissue Kit (Qiagen, Valencine, 
CA) (Figure 10). DNAs were then digested with HpaII enzyme: 100 ng of either tumor or normal 
DNA were digested with 10 U Hpa II restriction enzyme (New England Biolabs, Ipswich, MA, 
USA) at 37ºC overnight in a 20 µl reaction volume. Separate aliquots of DNA were subjected to 
mock digestion without the enzyme. After incubation, the restriction enzyme was inactivated at 65ºC 
for 20 min. HpaII-digested or mock-digested DNA was then subjected to PCR reaction, using the 
following primers: 5 FAM-labeled forward primer, 5’ACC GAG GAG CTT TCC AGA AT3’; 
reverse primer, 5’TGG GGA GAA CCA TCC TCA C3’. Thermal cycling conditions included the 
following steps: denaturation at 95°C for 10 minutes; 30 cycles at 95°C for 30 seconds, 55°C for 30 
seconds, and 72°C for 30 seconds; and a final extension at 72°C for 10 minutes. Products of PCR 
amplification were analyzed by gel and capillary electrophoresis. Gel electrophoresis was performed 
on 3% agarose gel containing ethidium bromide (10ug/ml), and resolved DNA bands were 
visualized on a UV transilluminator (Biorad). For capillary electrophoresis, PCR products were 
mixed with 95% formamide and loading buffer (5% blue dextran, 25 mM EDTA) containing Rox-
500. The mixture was then loaded on a 5% Long Ranger–6 M urea gel in TBE buffer. 
Electrophoresis was performed at 200 W for 2.25 hours, and the data were analyzed by an on a ABI 
3100 Genetic Analyzer (Applied Biosystems, Foster City, CA) and quantified by Genescan 3.1 
software (Applied Biosystems) (Figure 11). We used DNA extracted from female melanoma cell 
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line (labelled #1290) as a monoclonal control and DNA obtained from a healthy female blood 
sample (labelled L-IV-II) as a polyclonal control. 
 
 
 
 
 
 
 
 
Figure 10 Laser capture microdissection of MM. H&E of a representative MM tumor section is shown before A) and 
after B) tumor tissue was collected by laser capture microdissection. 
 
 
Figure 11 Schematic diagram of the HUMARA assay. Maternal and paternal X chromosomes carry different numbers 
of CAG repeats at the Humara locus. HpaII methylation sensitive sites are located at the polymorphic CAG region. 
During embriogenesis, random X chromosome inactivation occurs in female individuals, resulting in methylation of 
either the paternal or maternal X chromosome in different cells. Therefore, monoclonal cell population, derived from 
the division of a single ancestor cell, shares the same inactivated X chromosome, while a polyclonal population, 
derived from more than one ancestor cell, contain both cells with either inactive maternal or paternal X chromosome. 
HpaII digestion removes  the unmethylated alleles, allowing amplification of the methylated HUMARA locus. 
Electrophoresis of the PCR products will resolve respectively in a single band or two bands of different size. Arrows 
indicate the primer sites, HpaII denotes the methylation sensitive endonuclease sites; arrows indicate primer annealing 
regions. Cross bars indicate the methylated chromosome. 
 
 
A 
 
B 
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3.2.2 Data Analysis 
For each sample, the allele intensities were measured as the peak areas of both alleles, which is 
proportional to the molar amount of DNA. The allele ratios were first calculated by dividing the 
ratio (RU=A1U/A2U) of the non-HpaII digested sample, by the ratio (RD=A1D/A2D). The AR 
calculation (AR=RU/RD) corrects for any preferential amplification of one allele that might occur if 
the alleles are different in length. The clonality ratio is then calculated by dividing the AR of the 
tumor DNA by the AR calculated for the normal tissue (CR=ART÷ARN). This final calculation 
corrects for a potential skewed lyonization. A CR ≥ 3.0 or ≤ 0.3, representing a preferential loss of 
intensity in the digested sample of one of the two alleles present in the tumor sample, was scored as 
a monoclonal pattern. 
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4 RESULTS 
 
4.1 Mutational analysis of EGFR and downstream pathways 
 
4.1.1 Clinical Features 
Out of 77 MPM patients studied, 57 were male (74%) and 20 were female (26%); their average age 
at the time of diagnosis was 68 years (range 43–90, median 64.5 years). Of these, 50 patients 
(64.9%) had previously been exposed to asbestos at work. Histological examination showed that 59 
MPMs (77%) were epithelioid, 10 (13%) biphasic, and 8 (10.4%) sarcomatoid. In total, 41 patients 
had stage II tumours, 30 stage III tumours, and 6 stage IV tumours. Eastern Cooperative Oncology 
Group PS was 0–2 in 68 patients, and >2 in nine patients. In all, 41 patients were treated with 
platinum plus pemetrexed (Alimta) and 22 with platinum alone; 14 received no treatment because 
their performance status (PS) was >2 or because they refused. For this work we stopped the follow-
up (FU) at June 2012, at this date we collected FU data from 74 patients (three were lost to follow-
up). In all, 15 patients were still alive at June 2012 with a median FU of 24.5 months (range 14–39 
months). The median disease specific survival (DSS) of the cohort as a whole was 12.5 months 
(range 1–39 months) (Table 2). 
 
4.1.2 Mutational Analysis 
 
EGFR gene mutational profiling. 
No mutations were detected in the EGFR gene by direct sequencing or the Scorpions-ARMS assay, 
even though the latter has a sensitivity of 1% (vs the10–20% of direct sequencing). 
 
KRAS and BRAF gene mutational profiling.  
KRAS gene was successfully amplified in all of the samples, five of which showed mutations: two 
patients had the GGT-GtT point mutation in codon 12 leading to a glycine-to-valine amino-acid 
substitution (G12V); two had the GGC-GaC point mutation in codon 13 leading to a glycine-to 
aspartic acid substitution (G13D); and one had the rare GGC-aGC mutation in codon 13 leading to 
a glycine-to-serine substitution (G13S). Three of the five mutations occurred in patients with 
epithelioid MPMs (G12V, G13D, and G13S), one in a patient with a biphasic MPM (G13D), and 
one in a patient with a sarcomatoid subtype (G12V) (Table 2). All five patients with KRAS 
mutations reported previous occupational asbestos exposure. The BRAF gene mutational analysis 
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showed the classical valine to-glutamic amino-acid substitution in codon 600 (V600E) in three 
patients: two with epithelioid MPMs and one with a biphasic tumour (Table 2). None of them 
reported previous occupational asbestos exposure. 
 
PI3KCA gene mutational profiling. 
DNA of exons 9 and 20 of the PIK3CA gene was successfully amplified from 75 of the 77 
specimens. A point mutation was detected in only one case: it occurred in exon 20, and led to a 
methionine to isoleucine substitution in position 1040 (M1040I). The patient had a biphasic 
mesothelioma and no previous occupational asbestos exposure (Table 2). 
 
 
 
Table 2 Mutations in the EGFR downstream pathway were identified in nine patients (12%): five in the KRAS gene, 
three in the BRAF gene, and one in the PIK3CA gene. 
 
4.1.3 Statistical analysis. 
The correlations between the presence/absence of gene mutations and demographic, clinical and 
pathologic features (gender, age, occupational asbestos exposure, history of previous cancer, 
histological type, ECOG PS, treatment) were investigated, without finding any significant 
differences (Table 3).  
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Table 3 Correlations between the presence/absence of gene mutations and demographic, clinical and pathologic 
features 
 
 
The Kaplan-Meier analysis of the influence of some variables on long-term outcomes revealed no 
difference in DSS between the patients with and without gene mutations (P = 0.552). Moreover, 
separate evaluation of the patients with KRAS and BRAF mutations did not indicate any advantage 
in terms of DSS (P = 0.363 and P = 0.752) and, within the mutated group, no mutation significantly 
correlated with DSS (KRAS P = 0.363; BRAF P = 0.187). Interestingly, the patients with KRAS 
gene mutations reported occupational asbestos exposure, whereas those with BRAF and PI3KCA 
gene mutations did not. When the DSS of the patients with reported asbestos exposure was 
considered, the five KRAS gene mutated patients had a worse prognosis than those with wild-type 
KRAS (n=42), although the difference was not statistically significant (mean survival 9.20 ± 6.91 vs 
15.6 ± 10.39 months; P = 0.188). On the contrary, the DSS of the patients without reported 
occupational asbestos exposure was better in the BRAF gene mutated patients (n=3) than in those 
without BRAF mutations (n=22) although, once again, the difference was not statistically 
significant (mean survival 20.33 ± 12.06 vs 12.1 ± 8.37 months; P = 0.140) (Figure 12 A-B). 
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Figure 12 A) Kaplan-Meier DSS curves for MPM patients with KRAS mutation Vs wild-type B) and BRAF mutation 
Vs wild-type 
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4.2 Predictive and Prognostic Biomarkers 
 
4.2.1 Clinical features 
We collected 148 MPM specimens from patients who underwent pleural biopsy and/or surgical 
treatment. Out of 148 MPM patients studied, 103 were male (70%) and 45 were female (30%); their 
average age at the time of diagnosis was 75 years (range 27–90, median 65.3 years). Of these, 77 
patients (53%) had a history of occupational asbestos exposure, 65 had not been exposed (44%), six 
were lost to asbestos exposure information (3%). Histological examination showed that 108 MPMs 
(73%) were epithelioid, 20 (13,5%) biphasic, and 20 (13.5%) sarcomatoid. In all, 2 patients 
received Alimta, 80 patients were treated with platinum plus Alimta and 27 with platinum alone; 31 
received no treatment because their performance status (PS) was >2, because they refused or 
because advanced tumour, we were not able to collect the treatment information for 8 patients. For 
this we stopped  the follow-up at June 2013. At this date we collected disease specific survival 
(DSS) data from 145 patients (three were lost to follow-up). The median DSS of the cohort as a 
whole was 12.5 months (range 1–39 months); for alive patients the median DSS was 13 months 
(average 16,4 months; range 1–39 months) while for dead patients the median DSS was 8 months 
(average 10,5 months, range 1-39 months). 
 
4.2.2 Survival analysis 
We first investigated the correlation between the survival and the MPM histological subtype: the 
Kaplan-Meier curves and the statistical analysis carried out with Logrank test showed, as expected, 
a better prognosis in those patients with epithelioid MPM than in the biphasic and sarcomatoid (P = 
0.002) (Figure 13) (Montanaro et al, 2009). As shown in Figure 14, we analysed the correlation 
between DSS and treatment, finding that patients who received platinum plus Alimta had a better 
outcome than the other (P = 6.41e-08). Moreover we found a statistical correlation between age and 
DSS (P = 0.004) (Figure 15). 
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Figure 13 Kaplan-Meier analysis in MPM patients with different histotypes. B=biphasic; E=epithelioid; 
S=sarcomatoid 
 
 
Figure 14 Kaplan-Meier analysis in MPM patients who received different therapies. Alimta (solid line); Platinum 
(dashed line) Platinum+Alimta (dotted line); No therapy (dashed/dotted line) 
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Figure 15 Kaplan-Meier analysis in MPM patients divided in different age classes. 
 
4.2.3 ERCC1 Protein expression 
ERCC1 immuno-staining was successfully performed in all the 148 cases. The majority of the cases 
(92/148 - 62%) had H-score 3. Figure 16 shows in detail the distribution of the H-score values: 22 
cases had H-score 2  (22/148-14%), 5 cases 1.5 (5/148-3.5%), 13 cases 1 (13/148-9%), 4 cases 0.5 
(4/148-3%), 4 cases 0.1 (4/148-3%) and 8 cases were negative (8/148-5.5%). 
 
 
Figure 16 ERCC1 H-score values distribution. 92 cases showed a 3 value, 22 cases 2, 5 cases 1.5, 13 cases 1, 4 cases 
0.5, 4 cases 0.1 and 8 cases were negative. 
 
According to H-score values we divided the cases in two groups: ERCC1 positive (H-score ≥0.1) 
and ERCC1 negative (H-score =0); 140 patients were ERCC1 positive, 8 were negative. As shown 
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in Table 4, the two groups were correlated with clinical and pathological features: age, gender, 
asbestos exposure, histotype, status (dead-alive) and treatment, by Fisher’s exact test. We found a 
significant correlation between the ERCC1 protein expression and the status (P =0.008): ERCC1 
negative patients had a better prognosis than the ERCC1 positive. We performed the same statistical 
analysis using the median H-score value (3) as cutoff, but no significant correlations were found. 
Analysis of survival showed a significant correlation between ERCC1 protein expression and DSS 
positive (H-score ≥0.1; 141/148, 95%) and ERCC1 negative (H-score=0; 7/148, 5%) (Figure 17): 
patients with negative ERCC1 had a significantly better outcome when compared with the group 
with positive ERCC1 (Logrank test P=0.004) (Table 4). The same result was obtained in the 
subgroup of patients treated with platinum alone or in combination with Alimta (n=110) (Logrank P 
= 0.01), when we divided the population in two groups according to the H-score: ERCC1 negative 
(H-score =  0; 8/110) and ERCC1 positive (H-score ≥ 0.1; 102/110) (Figure 18). 
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ERCC1 H-score 
P-value 
(Fisher 
exact test) 
ERCC1 mRNA 
P-value 
(Kruskal-
Wallis test) 
Positive  
(H-score≥0.1) 
Negative  
(H-score=0) ≥ median value < median value  
TOT PATIENTS 140 (94.5%) 8 (5.5%) 57 (49.6%) 58 (50.4%) 
Age classes 
(27, 62] 29 3 
0.66  
13 10 
0.72 (62, 70] 35 2 14 13 (70, 75] 36 1 11 18 
(75, 90] 40 2 20 16 
Gender 
Male 95 8 1 42 39 0.36 Female 45 0 16 18 
Asbestos Exposure 
Yes 64 7 
0.70 
37 34 
0.96 No 70 1 21 19 
Unkown 6 0 0 4 
Histological Subtype 
Epithelial 101 7 
0.83 
38 44 
0.87 Biphasic 20 0 8 8 
Sarcomatoid 19 1 12 5 
Status* 
Alive 37 6 
0.008 
14 15 
0.85 Dead 100 2 42 42 
Lost at follow up 3 0 2 0 
DSS (dead patients) 2 9 14 0.004 1 7 10 0.76 1 DSS (alive patients) 2 13 (n=41) 25 (n=6) 17 (n=10) 23 (n=11) 
DSS (dead patients) 2;3 10.5 14 0.01 1 10.5 9.5 0.54 1 DSS (alive patients) 2;3 12.5 (n=40) 25 (n=6) 16 (n=17) 22.5 (n=12) 
Treatment 
Platinum 26 1 
0.29 
8 14 
0.006 
Alimta 2 0 1 1 
Platinum+Alimta 73 7 25 33 
None 31 0 18 8 
Unknow 8 0 6 1 
 
Table 4 Correlation between ERCC1 protein and mRNA levels and the clinical pathologic features of MPM 
patients.1Logrank test; 2 median value of DSS expressed in months; 3median value of DSS expressed in months 
evaluated in the subgroup of treated patients (platinum and platinum plus alimta). The median RQ value was 1.79. 
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Figure 17 Kaplan-Meier DSS curves in MPM patients showing negative (solid line) and 
positive (dashed line) ERCC1 protein levels. 
Figure 18 Kaplan-Meier DSS curves in MPM patients treated with platinum or 
platinum+Alimta showing negative (solid line) and positive (dashed line) ERCC1 protein 
levels. 
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4.2.4 ERCC1 Gene Expression 
ERCC1 mRNA was obtained in 115 cases. We observed very variable values: the median mRNA 
level value was 3.68 (average value 12.35; range from 0.18 to 163.76). The mRNA expression data 
were analysed continuously using the median value 3.68 as a cutoff in order to divided the whole 
population in two groups, ERCC1 positive (RQ ≥ 3.68, 58/115-50.4%) and ERCC1 negative (RQ < 
3.68, 57/115-49.6%). We correlated, by Kruskal-Wallis test, the two groups with the clinical and 
pathological features of the patients: age, gender, asbestos exposure, histotype, status (dead-alive) 
and treatment. As shown in Figure 19, the patients who were not selected for treatment (because of 
advance cancer, poor performance status or age), showed high level of ERCC1 mRNA (P=0.006) 
(Table 4) compared to those selected for treatment. The comparison between ERCC1 mRNA levels 
and DSS was not statistically significant in whole population, as well as in the subgroup of treated 
patients (categorised according to median value of RQ =3.68 and RQ =1.79 respectively) (Table 4). 
 
Figure 19 Box plot showing the correlation between ERCC1 mRNA levels and the selection for treatment. 
 mRNA levels are expressed as log(RQ). 
 
 
Finally, as shown in Figure 20, a significant association was found between ERCC1 gene and 
protein expression, though it is pretty weak (Kendall test, tau = 0.15, P = 0.032). 
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Figure 20 Scatter plot showing the correlation between ERCC1 protein and gene expression. mRNA levels are 
expressed as log(RQ). 
 
 
4.2.5 Thymidylate Synthase protein expression. 
TS immuno-staining was successfully performed in all the 148 cases. Figure 21 shows the 
distribution of H-score values: 4 cases showed  H-score 3 (3%); 11 cases 2 (7.5%); 15 cases 1.5 
(10%); 18 cases 1(12%); 17 cases 0.5 (11.5%); 6 cases 0.3 (4%); 11 cases 0.2 (7.5%); 18cases 0.1 
(12%) and 48 cases were negative (32.5%). An example of high and low TS protein expression in 
MPM is shown in Figure 22. According to the distribution of H-score values we divided the cases 
in two groups: TS positive (H-score ≥0.1) and TS negative (H-score =0). Out of 148 patients 100 
were TS positive (67.5%), and 48 were negative (32.5%). We correlated through Fisher’s exact test 
the two groups with the clinical and pathological features of the patients: age, histotype, gender, 
asbestos exposure, treatment and status (dead-alive); we did not find any correlation between TS 
protein expression and the characteristics above reported. Instead, when the whole population was 
categorised according to median H-score (0.2) (H-score = 0.2, 66/145-45.5%; H-score ≥ 0.2, 
79/145-54.5%; 3 lost to follow up) we observed a significant correlation between TS protein 
expression and the status (Fisher’s exact test P = 0.04), in detail the patients who showed high 
levels of TS had a better prognosis than the patients with low levels. In order to investigate the 
prognostic value of TS in MPM patients we performed a survival analysis but we did not find a 
significant correlation between DSS and TS protein levels. As Alimta inhibits TS enzymatic activity 
we investigated the predictive value of TS doing a survival analysis on MPM patients treated with 
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Alimta alone or in combination with platinum, but no correlation was found between TS protein 
expression and outcome (Table 5). 
 
Figure 21 TS H-score values distribution. 4 cases showed a 3 value; 11 cases 2; 15 cases 1.5; 18 cases 1; 17 cases 
0.5;6cases 0.3; 11 cases 0.2; 18cases 0.1 and 48 cases were negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Examples of TS expression in an MPM tumor section stained with anti-TS antibody (clone TS106, 
dilution 1:50) A) High TS expression B) Low TS expression. Original magnification 20X 
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TS  H-score 
P-value 
(Fisher 
exact test) 
TS mRNA P-value 
(Kruskal-
Wallis 
test) 
Positive  
(H score≥0.1) 
Negative  
(H-score=0) 
≥ median 
value 
< median  
value 
TOT PATIENTS 100 (67.5%) 
48  
(32.5%) 
47 
(50.5%) 
46  
(49.5%) 
Age classes 
(27, 62] 22 10 
0.51 
14 9 
0.65 (62, 70] 28 9 10 11 (70, 75] 25 12 9 14 
(75, 90] 25 17 14 12 
Gender 
Male 70 33 1 33 32 0.41  Female 30 15 14 14 
Asbestos Exposure 
Yes 53 24 
0.72 
25 26 
0.89 No 42 23 22 17 
Unkown 5 1 0 3 
Histological Subtype 
Epithelial 75 33 
0.66 
30 37 
0.30 Biphasic 12 8 7 5 
Sarcomatoid 13 7 10 4 
Status 
Alive 32 11 
0.24 
9 13 
0.49 Dead 65 37 36 33 
Lost to the follow up 3 0 2 0 
DSS (dead patients) 2 9 10 
0.39 1 
7 10 
0.111 DSS (alive patients) 2 13 (n=32) 25 (n=11) 18 (n=9) 23 (n=13) 
DSS (dead patients) 2;3  9 10 
0.92 1 
9 9 
0.75 1 DSS (alive patients) 2;3 13 (n=27) 24 (n=9) 18 (n=11) 25 (n=8) 
Treatment 
Platinum 17 10 
0.65 
8 10 
0.02 
Alimta 2 0 1 1 
Platinum+Alimta 56 24 19 28 
None 19 12 16 5 
Unknown 6 2 
  
 
Table 5 Correlation between TS protein and mRNA levels and the clinical pathologic features of MPM 
patients.1Logrank test, 2median value of DSS expressed in months; 3median value of DSS expressed in months evaluated 
in the subgroup of treated patients (alimta and platinum plus Alimta). The median RQ value was 2.77 
 
 
 
4.2.6 TS Gene Expression 
TS mRNA levels were successfully evaluated in 93 cases. We obtained very variable values: the 
median mRNA level value was 4,02 (average value 24,55; range to 0,17 to 615,85). The mRNA 
expression data were analysed continuously using median value 4,02 as a cutoff to divided the 
whole population in two groups, TS positive (RQ ≥4.02, 47/93-50.5%) and TS negative (RQ <4.02, 
46/93-49.5%). We correlated the two groups with the clinical and pathological features of the 
patients: age, gender, asbestos exposure, histotype, treatment, and status (dead-alive), using 
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Kruskal-Wallis test (Table 5). We observed a significant correlation between the TS mRNA levels 
and treatment selection (P=0.02): as shown in Figure 23 the patients who were not selected for 
treatment had higher level of mRNA than those who were selected for a therapeutic approach. To 
investigate the prognostic value of TS in MPM patients we performed a survival analysis but we did 
not find a significant correlation between DSS and TS mRNA levels; notable is the positive trend 
between DSS and TS mRNA levels until the 30th months (P = 0.12; Figure 24). We did not observe 
a significant correlation between TS gene expression and DSS in the subgroup of treated patients 
(patients treated with Alimta alone or in combination with platinum and categorised according to 
median value of RQ =2.77) (Table 5). 
 
Figure 23 Box plot showing the correlation between TS mRNA levels (expressed as log(RQ)) and the selection for 
treatment. 
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Figure 24 Kaplan-Meier DSS curves in MPM patients with high and low TS mRNA levels. Negative patients (solid 
line) show low mRNA levels (lower than the median RQ value chosen as cutoff); positive patients (dashed line) show 
high mRNA levels (higher than the median RQ velue chosen as cutoff). 
 
Furthermore, we studied the correlation between TS gene and protein expression. We performed a 
correlation analysis and, similarly to ERCC1, a significant association, though not too strong, 
between the protein and gene expression of TS was identified (Kendall test, tau = 0.21, P = 0.006) 
(Figure 25). 
 
Figure 25 Scatter plot showing the correlation between TS  protein and gene expression. mRNA levels are expressed 
as log(RQ). 
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By comparing ERCC1 and TS gene and protein expression, we found a statistically significant 
association in both cases, using respectively Pearson’s test (r2 = 0.88, P = 2.2e-16) and Kendall’s 
test (tau =0.16 P = 0.01) (Figure 26, Figure 27). 
 
Figure 26 Correlation analysis between ERCC1 and TS mRNA levels  
A=Alimta; P=platino; PA=platinum+Alimta; None=no treatment. mRNA levels are expressed as log(RQ) 
 
Figure 27 Correlation analysis between ERCC1 and TS protein levels. 
A=Alimta; P=platino; PA=platinum+Alimta; None=no treatment. 
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4.3 Clonality Assessment 
 
4.3.1 Sensitivity assay 
First we established the sensitivity of the HUMARA assay for the detection of under-represented 
alleles by both gel and capillary electrophoresis: different amounts of mono-allelic (HpaII-digested) 
and bi-allelic (HpaII non-digested) DNA from the 1290 melanoma monoclonal cell line were mixed 
in different proportions. PCR products were resolved by electrophoresis in 3% agarose and 
visualised under UV light in the presence of ethidium bromide, or by capillary electrophoresis and 
analysed by Genotypic Bioanalyzer (Applied Biosystems) (Figure 28 A-B). Linear regression of 
input vs detected allele ratios revealed a robust correlation (R2 >0.98), with the less frequent allele 
detectable when present at a fraction greater than or equal to 1 in 8 (12.5% of the input copies), 
Figure 29. 
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Figure 28 Sensitivity of the HUMARA assay by gel and capillary electrophoresis . A) Different amounts of HpaII-
digested and non-digested DNA from the monoclonal melanoma cell line 1290 were mixed and subjected to PCR for 
detection of HUMARA locus. PCR products were resolved on a 3% agarose gel containing Ethidium Bromide and 
detected under UV light. The minor allele was visible in PCR reactions containing as little as 25% of the bi-allelic 
sample. N denotes the no template control. 100, 75, 50, 25 and 0 indicate the percentage of bi-allelic DNA in the PCR 
reaction.B) PCR products were resolved onto the Applied Biosystems 3100 Genetic Analyser. CTR denotes the no 
template control. 100, 75, 50, 25, 12.5, 6.25 and 0 indicate the percentage of bi-allelic DNA in the PCR reaction.  
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Figure 29 Linear regression analysis calculated with Prism 6 software, shows comparison between input and 
detected allelic/biallelic ratios calculated using Genescan software. (R2 >0.98).  
 
 
 
4.3.2 Clonality analysis. 
HUMARA clonality assays were carried out in 14 sporadic and 2 familial (i.e. harbouring BAP1 
mutation), Stage I to III biopsies resected from 14 female MM patients, who underwent surgery 
(Table 6). In two out of 14 sporadic cases, two distinct nodules were collected and analysed. 
Pathological evaluation revealed absence of tumour cells in all the normal microdissected tissues 
and less that 5% normal infiltrating cells in all microdissected tumour samples included in this 
study. As a control, we performed HUMARA assay on healthy male DNA (bearing a single 
unmethylated, active X chromosome), shown as a single PCR band/peak, indicating complete DNA 
digestion by HpaII enzyme, hence a lack of bias in the HUMARA assay, due to possible incomplete 
digestion (Figure 30). As additional controls, HUMARA assay was also performed on a healthy 
female DNA sample (L IV-II) and on DNA from a melanoma cell line (#1290, female): as shown in 
Figure 30, gel and capillary electrophoresis successfully detected a polyclonal and a monoclonal 
pattern, respectively. Samples were classified as non-informative when a single band or peak was 
detected in the nearby normal tissue, after digestion with the HpaII enzyme, indicating the presence 
of skewed lionization, an event that occurs in about 10% of a healthy female population (Vickers et 
al, 2001). Out of 16 samples tested, 14 were informative. We found two non-informative samples: 
one case (#1359, a sporadic MM) is shown in Figure 31, PCR amplification of mock-digested DNA 
produced two bands/peaks, while only one band/peak was observed after treatment with HpaII, 
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indicating skewed (non-random) X chromosome inactivation. In the second case (L-III-18, a 
familial MM case), PCR amplification of both mock- and HpaII-digested DNA produced a single 
band, indicating that the lengths of the paternal and maternal alleles were identical. Of the 14 
informative samples, 13/14 PCR products (93%) displayed two distinct bands and peaks. 11 
representative samples are shown in Figure 31. Corrected Allele Ratio (CR) calculated on the allele 
peak areas by Genotypic Bioanalyzer was ≥0.3 in all 13 samples indicating a polyclonal origin of 
MM tumours (Figure 31 B). Case #524 showed a quite distinct pattern, as one nodule (#524B) 
revealed a monoclonal pattern (CR ≤0.3), while the other (#524A) was polyclonal. 
 
 
Table 6 Clinical features and clonality pattern in 16 biopsies from 14 MM female patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample ID Age Inheritance Histology Staging Clonality 
6 ND Sporadic Biphasic NA Polyclonal   
61 82 Sporadic Epithelioid III Polyclonal 
93 64 Sporadic Epithelioid III Polyclonal 
207A 
207B      
74 Sporadic Epithelioid III Polyclonal 
Polyclonal 
273 66 Sporadic Biphasic III Polyclonal 
524A 
524B 
72 Sporadic Epithelioid III Polyclonal 
Monoclonal 
851 58 Sporadic Biphasic III Polyclonal 
1250  65 Sporadic Epithelioid III Polyclonal 
1359 56 Sporadic Epithelioid III Non-informative 
1419 25 Sporadic Biphasic III Polyclonal 
LIII18 64 Familial Epithelioid III Non-informative 
R088 59 Sporadic Epithelioid III Polyclonal 
R693 63 Sporadic Epithelioid I Polyclonal 
WIII6 66 Familial Epithelioid II Polyclonal 
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Figure 30 Quality controls. A) Humara-PCR was performed on HpaII-digested (H+) and mock-
digested (H-) DNA from a healthy male and analyzed by capillary electrophoresis, using the 3100 
Genome analyzer. Presence of a single PCR peak indicated complete DNA digestion by HpaII 
enzyme. B) Healthy female DNA sample (L-IV-II) and DNA from a human monoclonal melanoma 
cell line (#1290, female) were subjected to HUMARA assay. Capillary electrophoresis successfully 
detected a polyclonal pattern and a monoclonal pattern 
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Figure 31 X chromosome inactivation analysis by HUMARA assay shows both monoclonal and polyclonal pattern 
of Malignant Mesotheliomas. A) Gel electrophoresis and B) Capillary Electrophoresis. Analysis of a panel of 
representative MM samples. Gel electrophoresis A). PCR products from mock digested (H-) and HpaII-digested (H+) 
samples were separated on a 3% agarose gel and visualized under UV light, using ethidium bromide. B) Capillary 
Electrophoresis. HUMARA PCR assay was performed using a 5FAM-labeled forward primer, and quantified by the 
Applied Biosystems 3100 Genetic Analyser. Two major peaks marked with the blue bar denote the two allelic 
HUMARA loci amplified in PCR HpaII-digested (H+) and mock-digested samples (H-). The allele intensities were 
measured as peak area of both alleles, which is proportional to the molar amount of DNA. Peak areas were calculated 
for each allele by using Genescan software. N denotes normal nearby tissue samples, while T indicates the tumor 
samples. A and B indicate independent tumour nodules obtained from the same patient. Sample #1359 was analyzed as 
a non-informative sample, as a single band/peak (CR=2.06) was detected after HpaII digestion of the normal tissue 
counterpart indicating a skewing of the X-chromosome inactivation. 
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5 DISCUSSION 
 
5.1 Mutational analysis of EGFR and downstream pathway in pleural 
malignant mesothelioma samples. 
 
As EGFR is involved in the carcinogenesis of MPM, it is possible that EGFR-targeted therapies 
may be efficacious in MPM patients (Barbieri et al, 2011). EGFR TKI inhibitors, such as gefitinib 
and erlotinib, inhibit MPM cell migration and proliferation, enhance the response to radiation of 
human MPM cell lines, and reduce motility and invasion in MPM cell lines (Kurai et al, 2012). 
However, the promising results obtained in in vitro studies were not reproduced in two phase II 
trials involving patients with pleural and peritoneal mesotheliomas, although it should be noted that 
neither study evaluated the mutation status of the EGFR gene and its downstream signalling 
transduction pathway (Garland et al, 2007; Govindan et al, 2005). As in the case of colorectal 
cancer and lung adenocarcinoma, this lack of molecular selection could explain the therapeutic 
failure. The few studies that have sought mutations in the tyrosine kinase domain of the EGFR gene 
in patients with malignant mesotheliomas involved small populations and used a relatively 
insensitive method (the direct sequencing of exons 18-21) (Cortese et al, 2006; Enomoto et al, 
2012; Velcheti et al, 2009). The primary objective of the first part of our study was to look for 
EGFR gene mutations in a larger series of patients (n=77) using two molecular methods: all of the 
cases were first screened using Scorpion-ARMS technology, which is capable of detect 1% of 
mutated cells against a 99% background of wild-type cells, followed by direct sequencing in order 
to find rarer mutations or mutations that cannot be detected using the first method. However, 
despite this, we did not find any mutations in the TK domain of EGFR: in addition to confirming 
previous findings (Cortese et al, 2006; Velcheti et al, 2009), this also indicates that, unlike in the 
case of lung adenocarcinomas, mutations cannot be detected even when real-time PCR is used to 
increase sensitivity (Allegrini et al, 2012). On the contrary, Enomoto et al. have recently studied 38 
patients and found EGFR missense mutations in exons 18 (n=1), 20 (n=3) and 21 (n=1) in six 
(16%) patients with pleural (n=3) or peritoneal mesotheliomas (n=3) (Enomoto et al, 2012). EGFR 
gene mutations have been previously found in peritoneal mesotheliomas (Foster et al, 2009; Foster 
et al, 2010), but this is the only published report of EGFR gene mutations in MPM. However, the 
study involved Japanese patients, who are characterised by more frequent EGFR gene mutations in 
lung adenocarcinoma than Western patients (Endo et al, 2005). Furthermore, some of the detected 
mutations had never been reported before, and their biological and clinical significance is still 
unknown. An alternative method of blocking EGFR is to use monoclonal antibodies (mABs), which 
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may be extremely useful as it has been demonstrated that MPM patients show EGFR gene 
amplification (Dazzi et al, 1990; Destro et al, 2006; Okuda et al, 2008). No published studies have 
assessed the in vivo effects of anti-EGFR mAbs on MPMs, although one recent study has found that 
cetuximab is highly efficacious in cultured MPM cell lines (Kurai et al, 2012). It has been 
demonstrated that mutations in EGFR downstream pathways can affect the efficacy of EGFR mABs 
in other tumours such as colorectal adenocarcinoma) (Jonker et al, 2007), and we found nine 
patients (11.7%) with missense mutations involving the KRAS (n=5), BRAF (n=3) and PIK3CA 
genes (n=1). Few other studies have separately investigated the presence of mutations in KRAS, 
BRAF and PIK3CA genes in MPM samples and mesothelioma cell lines without success (see review 
by Argawal et al., 2010) but, to the best of our knowledge, our study first investigated these 
alterations systematically in a large series of MPM patients. Various reasons may explain these 
discrepant results. We screened a large number of samples (n=77), whereas the other studies were 
based on smaller series and may have underestimated the real frequency of such mutations. 
Furthermore, we analysed KRAS gene mutations using a mutant-enriched PCR (ME-PCR) 
technology whose sensitivity is 0.1% (Molinari et al, 2011), and so it is possible that the percentage 
of KRAS gene mutated cells is very low in MPM and that more widely used sequencing methods are 
unable to detect small clones. Our findings show that, although infrequent, mutations in EGFR 
downstream pathways can be found in MPMs, thus supporting the hypothesis that EGFR mABs 
may be clinically effective in the majority of patients. On the other hand, patients with a molecular 
profile indicating putative resistance to EGFR mABs (because of the presence of KRAS or BRAF or 
PIK3CA mutations) may be directed towards new targeted therapies. One recent study has shown 
vemurafenib is promising not only in patients with metastatic melanoma, but also in patients with 
non-small lung cell cancer carrying a BRAF mutation (Gautschi et al, 2012), and selumetinib and 
BYL-719, which target KRAS and PIK3CA mutations are currently being evaluated in several 
clinical trials (Clinical Trials Magnifier). Our data therefore underline importance of the molecular 
characterisation of patients with MPM. The clinical implications of the gene mutations detected in 
our study are not clear. DSS did not differ between patients with or without gene mutations 
(whether analysed together or separately). Interestingly, all of the patients with KRAS gene 
mutations reported occupational asbestos exposure, but none of those with BRAF or PIK3CA gene 
mutations. Comparison of mean DSS in the KRAS and BRAF gene mutated patients Vs wild-type 
patients previously exposed to asbestos or not showed that the KRAS gene mutated patients 
(n=5/50) tended to have a worse prognosis than the wild-type patients (9.20 ± 6.91 Vs 15.6 ± 10.39 
months), and the BRAF gene mutated patients (n=3/27) tended to have a better prognosis (20.33 ± 
12.06 Vs 12.1 ± 8.37 months). However, the differences were not statistically significant and our 
findings need to be confirmed in larger series of MPM patients. In conclusion, our extensive 
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molecular characterisation of EGFR pathways may explain the failure of TKI administration and 
may open up the possibility of developing new targeted therapies. 
 
 
5.2 Prognostic and predictive biomarkers in malignant pleural mesothelioma. 
 
Malignant pleural mesothelioma is a disease with high resistance against different forms of 
oncology therapy. The combination of platinum (cisplatin/carboplatin) and pemetrexed represents 
the standard of care in the first-line treatment of MPM. However, more than one third of patients do 
not respond to this schedule and are exposed to useless toxicity. It is now recognized that the way a 
patient responds to chemotherapy is a complex trait, influenced by the tumour characteristics and 
individual genetic constitution: therefore, patient selection on the basis of prognostic and predictive 
biomarkers is crucial for maximising therapeutic efficacy and minimising useless treatment. The 
aim of this study was to find valid biomarkers to select patients who can receive more advantage 
from the treatment with standard chemo agents. On the basis of previous studies carried out on 
NSCLC, we selected ERCC1 and TS for our investigation and we evaluated prognostic and 
predictive value of both protein and transcript level. Since platinum acts through the formations of 
adducts to DNA and ERCC1 is involved in mechanisms of DNA repair (NER system), the initial 
hypothesis was that low levels of ERCC1 in tumour cells should be related to A) high response rate 
in patients treated by platinum based chemotherapies, and B) decrease survival in untreated patients 
due to the reduced ability to repair the DNA damages. Conversely, high levels of ERCC1 might be 
related to resistance to platinum therapy and improved outcome in non-treated patients. We  
evaluated ERCC1 levels in tumour cells through the analysis of protein expression, by means of 
immunohistochemistry -a technique used in most pathology laboratories- or by gene expression 
assessment obtained by mRNA extraction and amplification. The latter method gives more accurate 
information even if it is quite difficult to perform in routinely treated samples. We  performed both 
analyses in an effort to identify the more reliable method and to compare the results of both 
analyses with the main prognostic and predictive parameters. Firstly we noticed that in those 
patients not selected for any treatment because of poor performance status, advanced cancer or age, 
both ERCC1 and TS showed high mRNA levels. A possible explanation could be that in advanced 
MPM tumor cells have a high division rate, TS is strongly activated, as it is involved in DNA 
synthesis. At the same time, in the high proliferative cells, DNA damages occurs more often than in 
the normal cells thus causing a strong activity of the enzymes involved in the DNA repair, such as 
ERCC1. Statistical analysis carried out on ERCC1 showed that patients negative for its protein 
expression had significant better survival (evaluated by alive-dead and by DSS) than those who 
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were ERCC1 positive, independently from the intensity of staining (evaluated as H-score). These 
results were obtained both in the whole cohort (n=148) and in the subgroup of the treated patients 
(n=110). Since the latter group was more numerous than the group of non-treated patients, the result 
seems to indicate that the lack of expression of ERCC1 appears to have a predictive rather than a 
prognostic significance and it should be used to identify patients eligible for platinum based 
treatment. On the contrary, the statistical analysis of ERCC1 gene expression did not show any 
prognostic and predictive significance. The discrepancy in the correlation to survival between 
protein and gene expression could be explained by the fact that we found a weak correlation 
between ERCC1 gene and protein expression, possibly suggesting some  translational or post 
translational mechanism. Numerous studies, performed in several solid organ tumours, 
demonstrated that ERCC1 mRNA levels predict response to treatment and/or survival. For example, 
high levels of ERCC1 mRNA in pre-treated ovarian and gastric tumour tissue have been associated 
with platinum resistance (Dabholkar et al, 1994; Metzger et al 1998). Similarly, in non-small cell 
lung cancer (NSCLC), in patients treated with platinum-based chemotherapy, low or undetectable 
levels of ERCC1 mRNA, or protein expression predict better survival (Lord et  al, 2002; Olaussen 
et al, 2006). Recently Zucali et al have investigated the role of ERCC1 protein and gene expression 
in a series of 63 patients with MPM treated by standard chemotherapy finding no association with 
the outcome; similar results were also obtained by Righi et al in a study performed on 60 MPM 
patients. Our results, obtained in a larger series of MPM specimens, suggest that ERCC1 protein 
evaluation by immunohistochemistry could represent a useful tool to select patients potentially 
responding to chemotherapy. Pemetrexed (Alimta) inhibits multiple enzymes in the folate metabolic 
pathway, and thymidylate syntase (TS) is the main target (Shih et al, 1997). In NSCLC cell lines, 
high baseline TS gene expression levels conferred resistance to pemetrexed (Giovannetti et al. 
2007) and TS levels were correlated to pemetrexed efficacy in a variety of solid tumors (Gomez et 
al, 2006, Rose et al, 2002). TS mRNA and protein expression levels might also play a prognostic 
role, as reported in patients with NSCLC (Shintani et al, 2003; Hashimoto et al, 2006). In our study 
the correlation between TS protein expression and status (dead-alive) was evaluated by using two 
parameters (positive Vs negative staining and under Vs above median H-score value). No 
correlation was found with survival when patients were divided in positive and negative. In 
contrast, when the median H-score value of 0.2 was selected, a significant correlation with the 
status was found, indicating that patients with low levels of TS protein had a higher mortality than 
those with high TS protein levels, thus assuming a negative prognostic value. TS gene expression 
did not show any statistically significant correlation either with patient status and DSS. However, 
the Kaplan-Meier curves showed a favorable trend for patients with low levels of mRNA (lower 
than cutoff =4.02) up to the 30th month of follow up indicating a tendency to predict a positive 
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response to the treatment with Alimta alone or in combination. So far, only Zucali et al established 
a significant predictive correlation between low TS mRNA levels and longer overall survival in 
treated patients. In conclusion, the role of TS assessment is worth of prospective validation in future 
studies on MPM. Moreover we plan to further investigate the gene expression of TS and ERCC1 in 
a wider number of MPM cases to obtain more accurate data and to set up prospective studies in 
order to confirm the potential role of ERCC1 as a predictive and prognostic biomarker in MPM 
patients. 
 
 
5.3 Evaluation of clonal origin of malignant mesothelioma. 
 
Malignant mesothelioma (MM) is a lethal cancer affecting approximately 3,200 individuals each 
year in the US (Hanley et al, 2013), most of whom die within 1 year from diagnosis. At diagnosis 
MMs are histologically complex, comprising different histologic types, epithelioid, sarcomatoid and 
biphasic, and among them there are also subtypes with distinct histologic characteristics. Diagnosis 
is further complicated by the presence of intra-tumoural pleomorphism and phenotypic 
heterogeneity, raising the question of whether MM result from genetic and epigenetic alterations 
which drive clonal tumour evolution into these different morphologies, or whether mesotheliomas 
arise from different subsets of mesothelial cells that become malignant more or less at about the 
same time. Multistep carcinogenesis is the currently accepted hypothesis to explain genetic 
diversity in tumours (Aparicio et al, 2013; Greaves et al, 2012).This hypothesis is based on the idea 
that somatic mutations are rare events: during the process of cellular transformation and 
development of a neoplasm, multiple genetic events are known to accumulate in the neoplastic 
cells. However, it is unlikely that multiple events occur in a single cell. Although clonal evolution 
of cancer is likely to occur irrespective of its origin, identifying whether a tumour is monoclonal or 
polyclonal at start, have critical implications in terms of early therapeutic intervention. A tumour is 
considered monoclonal when all cells within the tumour can be traced back to a single 
progenitor/initiator cell. A tumour which is polyclonal at origin, on the other hand, derives from the 
concomitant transformation of two or more different ancestor cells. To the best of our knowledge 
the clonal origin of MM has never been investigated, and MM are assumed to be “clonal” as 
tumours are generally assumed to be mostly clonal. When patients with very early stage of MM 
(Stage Ia), such as individuals affected by the BAP1 cancer syndrome, are examined, the presence, 
even at such an early stage, of many minuscule pleural nodules (~1 mm in max diameter), has been 
noted. The finding of multiple pleural nodules in a patient at the earliest possible MM stage raised 
the question of whether these nodules represented independent growth processes. According to the 
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current dogma, based on the hypothesis of tumour monoclonality, it should be instead that a single 
monoclonal tumour nodule shed cells in the pleural space that subsequently seeded the pleura. To 
address whether MM have monoclonal or polyclonal origin, we performed the HUMARA assay 
(Allen et al, 1992). Of the 14 informative samples, 13/14 PCR products (93%) displayed two 
distinct bands and peaks. Surprisingly, one case (#524) showed a quite distinct pattern, as one 
nodule (#524B) revealed a monoclonal pattern (CR ≤0.3), while the other (#524A) was polyclonal. 
This finding may indicate that, within a largely polyclonal tumour, composed by clones derived 
from different cells of origin, a particular clone dominates a certain area. Different hypothesis may 
be proposed to explain this finding. X-chromosome inactivation based assays may detect a 
seemingly monoclonal tumour when transformation occurs in multiple cells with the same 
inactivated X chromosome. Although possible, this is a rare event, mainly dependent on the X-
inactivation patch size, due to occurrence of lyonization early in development, which leads few of 
the progeny of a single embryonic stem cell to be grouped together in the adult, forming patches. A 
similar phenomenon has been described in breast tissues, which display a rather large patch size 
(Novelli et al, 2003). Alternatively, a true monoclonal nodule may result from the clonal outgrow of 
a cell which acquired a proliferative advantage. An example is the loss of X-linked FOXP3 gene 
found in breast and prostate cancer (Zuo et al; 2007 Wang et al, 2009) Surprisingly, loss of one of 
the few known X-linked tumour suppressor genes, GPC3, has already been associated to malignant 
mesothelioma (Murthy et al, 2000). In collaboration with the Hawaii Cancer Center, we are 
currently investigating the status of X-linked tumour suppressor genes in samples #524B compared 
to #524A and other polyclonal MM tumours. In conclusion, our data indicate that MM may arise as 
polyclonal tumours due to concurrent transformation of multiple mesothelial cells. X-chromosome 
studies conducted in some other cancer types indicating a polyclonal origin in some breast and 
colon carcinomas (Parsons B., 2008; Xin L., 2013), support our findings that not all tumours are 
monoclonal. The notion that tumours derive from a single cell through the expansion and evolution 
of several clones has survived almost unchallenged till present. Accordingly, much effort has been 
placed in dissecting the clonal relationships present within single tumours (Aparicio et al, 2013). 
Our finding that MM are polyclonal at the origin indicates that MM are likely to be clonally 
complex at the outset. This suggests that not only clonal cancer evolution, but also polyclonal origin 
of tumours contribute to the intra-tumoural heterogeneity and emergence of drug-resistant 
subpopulations. A critical implication of this finding is that only tracking the clonal evolution of 
tumours may not be sufficient to successfully target MM tumours, providing a possible explanation 
for the peculiar resistance of MM to current therapies. Instead there is a need to attack 
simultaneously several different molecular targets, even at early stages of MM development, to 
eliminate unrelated cell clones, carrying their own distinct set of molecular alterations. Our findings 
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may explain why patients whose tumours are removed at Stage I often experience MM recurrence a 
few years after surgery, in spite of apparent successful tumour eradication. In contrast to the current 
thinking, recurrence likely represents novel malignancies occurring on other areas of the pleura 
because of the carcinogenic “field effect” of asbestos and of other mineral fibers and/or because of 
ubiquitous genetic predisposition. The findings present in this study are relevant to the 
understanding of human cancer development, and provide a new standpoint for development of 
effective cancer treatments.  
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